Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center
Background: Mucormycosis is an angioinvasive mucorales fungal infection. Cutaneous type formed 10.5% of cases in India in precovid-19 era. Glucocorticoid-induced immunosuppression and hyperglycemia, reusable oxygen humidifiers in COVID-19 therapy, and preexisting uncontrolled diabetes mellitus contr...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2022-01-01
|
| Series: | Indian Journal of Dermatology |
| Subjects: | |
| Online Access: | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=2;spage=206;epage=206;aulast=Abhirami |
| _version_ | 1811343799485464576 |
|---|---|
| author | B Abhirami Prabhat Kumar Dharmendra Kumar Mishra Satyendra Prasad Yadav |
| author_facet | B Abhirami Prabhat Kumar Dharmendra Kumar Mishra Satyendra Prasad Yadav |
| author_sort | B Abhirami |
| collection | DOAJ |
| description | Background: Mucormycosis is an angioinvasive mucorales fungal infection. Cutaneous type formed 10.5% of cases in India in precovid-19 era. Glucocorticoid-induced immunosuppression and hyperglycemia, reusable oxygen humidifiers in COVID-19 therapy, and preexisting uncontrolled diabetes mellitus contribute to post-COVID-19 mucormycosis. However, for post-COVID-19 cutaneous mucormycosis, sufficient data is not available. Aim: To study factors related to post-COVID-19 cutaneous mucormycosis. Methodology: Clinical and investigation details of six patients admitted in tertiary center with post-COVID-19 cutaneous mucormycosis. Results: Among six patients, three were males and three females; all in 45–60 years age group from districts under tertiary center. Site of eschar was face (four) and lips (two). All six were positive for COVID-19 10–12 days prior to admission for mucormycosis. All had intravenous steroids and supportive humidified oxygen therapy for minimum 1 week under COVID-19 treatment. They presented to emergency with ophthalmic/ENT complaints; subsequently, they developed cutaneous manifestations within 2–3 days. All six had diabetes mellitus, with above 400 mg/dL sugar levels at admission. Conclusion: This study's findings correlated with various studies across the country and elsewhere. Preexisting diabetes mellitus and steroid therapy for COVID-19 increase the risk of mucormycosis. Caution for early diagnosis, maintaining blood glucose levels, and judicious use of steroids for treatment of COVID-19 are indicated. |
| first_indexed | 2024-04-13T19:35:18Z |
| format | Article |
| id | doaj.art-3d792e33d030484d9657fce2a5f59d8a |
| institution | Directory Open Access Journal |
| issn | 0019-5154 1998-3611 |
| language | English |
| last_indexed | 2024-04-13T19:35:18Z |
| publishDate | 2022-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Indian Journal of Dermatology |
| spelling | doaj.art-3d792e33d030484d9657fce2a5f59d8a2022-12-22T02:33:02ZengWolters Kluwer Medknow PublicationsIndian Journal of Dermatology0019-51541998-36112022-01-0167220620610.4103/ijd.ijd_781_21Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary centerB AbhiramiPrabhat KumarDharmendra Kumar MishraSatyendra Prasad YadavBackground: Mucormycosis is an angioinvasive mucorales fungal infection. Cutaneous type formed 10.5% of cases in India in precovid-19 era. Glucocorticoid-induced immunosuppression and hyperglycemia, reusable oxygen humidifiers in COVID-19 therapy, and preexisting uncontrolled diabetes mellitus contribute to post-COVID-19 mucormycosis. However, for post-COVID-19 cutaneous mucormycosis, sufficient data is not available. Aim: To study factors related to post-COVID-19 cutaneous mucormycosis. Methodology: Clinical and investigation details of six patients admitted in tertiary center with post-COVID-19 cutaneous mucormycosis. Results: Among six patients, three were males and three females; all in 45–60 years age group from districts under tertiary center. Site of eschar was face (four) and lips (two). All six were positive for COVID-19 10–12 days prior to admission for mucormycosis. All had intravenous steroids and supportive humidified oxygen therapy for minimum 1 week under COVID-19 treatment. They presented to emergency with ophthalmic/ENT complaints; subsequently, they developed cutaneous manifestations within 2–3 days. All six had diabetes mellitus, with above 400 mg/dL sugar levels at admission. Conclusion: This study's findings correlated with various studies across the country and elsewhere. Preexisting diabetes mellitus and steroid therapy for COVID-19 increase the risk of mucormycosis. Caution for early diagnosis, maintaining blood glucose levels, and judicious use of steroids for treatment of COVID-19 are indicated.http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=2;spage=206;epage=206;aulast=Abhiramicutaneous mucormycosisdiabetes mellitusescharpost-covid-19steroid induced |
| spellingShingle | B Abhirami Prabhat Kumar Dharmendra Kumar Mishra Satyendra Prasad Yadav Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center Indian Journal of Dermatology cutaneous mucormycosis diabetes mellitus eschar post-covid-19 steroid induced |
| title | Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center |
| title_full | Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center |
| title_fullStr | Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center |
| title_full_unstemmed | Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center |
| title_short | Secondary cutaneous mucormycosis post-COVID-19: Case series from a tertiary center |
| title_sort | secondary cutaneous mucormycosis post covid 19 case series from a tertiary center |
| topic | cutaneous mucormycosis diabetes mellitus eschar post-covid-19 steroid induced |
| url | http://www.e-ijd.org/article.asp?issn=0019-5154;year=2022;volume=67;issue=2;spage=206;epage=206;aulast=Abhirami |
| work_keys_str_mv | AT babhirami secondarycutaneousmucormycosispostcovid19caseseriesfromatertiarycenter AT prabhatkumar secondarycutaneousmucormycosispostcovid19caseseriesfromatertiarycenter AT dharmendrakumarmishra secondarycutaneousmucormycosispostcovid19caseseriesfromatertiarycenter AT satyendraprasadyadav secondarycutaneousmucormycosispostcovid19caseseriesfromatertiarycenter |